William J. Valentine

4.7k total citations
140 papers, 3.6k citations indexed

About

William J. Valentine is a scholar working on Endocrinology, Diabetes and Metabolism, Economics and Econometrics and Surgery. According to data from OpenAlex, William J. Valentine has authored 140 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Endocrinology, Diabetes and Metabolism, 35 papers in Economics and Econometrics and 20 papers in Surgery. Recurrent topics in William J. Valentine's work include Diabetes Treatment and Management (95 papers), Diabetes Management and Research (90 papers) and Health Systems, Economic Evaluations, Quality of Life (34 papers). William J. Valentine is often cited by papers focused on Diabetes Treatment and Management (95 papers), Diabetes Management and Research (90 papers) and Health Systems, Economic Evaluations, Quality of Life (34 papers). William J. Valentine collaborates with scholars based in United States, United Kingdom and Switzerland. William J. Valentine's co-authors include Andrew Palmer, Jayne Smith‐Palmer, Stéphane Roze, Barnaby Hunt, Morten Lammert, Giatgen A. Spinas, V. Foos, Michael E. Minshall, Joshua Ray and Richard F. Pollock and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and Diabetes Care.

In The Last Decade

William J. Valentine

137 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William J. Valentine United States	34	2.4k	657	575	535	476	140	3.6k
Carola Grönhagen‐Riska Finland	38	689 0.3×	1.3k 2.0×	314 0.5×	547 1.0×	508 1.1×	120	4.9k
Holly K. Van Houten United States	25	787 0.3×	611 0.9×	230 0.4×	299 0.6×	93 0.2×	75	2.4k
Ronac Mamtani United States	35	370 0.2×	1.2k 1.8×	206 0.4×	567 1.1×	1.1k 2.4×	215	4.0k
Scott Chasan-Taber United States	19	376 0.2×	1.1k 1.7×	236 0.4×	524 1.0×	471 1.0×	25	4.3k
Stephen S. Johnston United States	28	510 0.2×	748 1.1×	261 0.5×	329 0.6×	206 0.4×	135	3.2k
Brian Shine United Kingdom	33	1.2k 0.5×	927 1.4×	59 0.1×	785 1.5×	286 0.6×	127	3.8k
J. L. Botha United Kingdom	21	895 0.4×	342 0.5×	96 0.2×	360 0.7×	205 0.4×	61	2.0k
Mary A. De Vera Canada	35	217 0.1×	869 1.3×	229 0.4×	423 0.8×	347 0.7×	160	3.9k
Robin J. Larson United States	20	607 0.3×	425 0.6×	63 0.1×	589 1.1×	166 0.3×	29	2.2k
Cornelis Boersma Netherlands	17	228 0.1×	416 0.6×	492 0.9×	246 0.5×	142 0.3×	78	2.5k

Countries citing papers authored by William J. Valentine

Since Specialization

Citations

This map shows the geographic impact of William J. Valentine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William J. Valentine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William J. Valentine more than expected).

Fields of papers citing papers by William J. Valentine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William J. Valentine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William J. Valentine. The network helps show where William J. Valentine may publish in the future.

Co-authorship network of co-authors of William J. Valentine

This figure shows the co-authorship network connecting the top 25 collaborators of William J. Valentine. A scholar is included among the top collaborators of William J. Valentine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William J. Valentine. William J. Valentine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yale, Jean‐François, et al.. (2022). Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis. Journal of Medical Economics. 25(1). 238–248. 1 indexed citations

Argüelles‐Arias, Federico, Fernando Bermejo, Joaquín Borrás‐Blasco, et al.. (2022). Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therapeutic Advances in Gastroenterology. 15. 1098269107–1098269107. 1 indexed citations

Aksan, A, et al.. (2021). Evaluation of the Cost-Effectiveness of Iron Formulations for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease in the UK. ClinicoEconomics and Outcomes Research. Volume 13. 541–552. 14 indexed citations

Norrbacka, Kirsi, et al.. (2020). Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. The European Journal of Health Economics. 21(8). 1179–1196. 9 indexed citations

Aksan, A, Alain Schoepfer, Pascal Juillerat, et al.. (2020). Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. Advances in Therapy. 38(1). 660–677. 15 indexed citations

Ali, Sarah, et al.. (2020). Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Journal of Medical Economics. 23(6). 650–658. 30 indexed citations

Petitjean, Audrey, Jayne Smith‐Palmer, William J. Valentine, B. Téhard, & Stéphane Roze. (2019). Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. BMC Cancer. 19(1). 140–140. 8 indexed citations

Hunt, Barnaby, Brian Bekker Hansen, Åsa Ericsson, et al.. (2019). Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Advances in Therapy. 36(12). 3483–3493. 18 indexed citations

Mitchell, Beth, et al.. (2019). Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis. Journal of Diabetes Science and Technology. 13(5). 910–918. 13 indexed citations

10.

Bain, Stephen C., Brian Bekker Hansen, Barnaby Hunt, Barrie Chubb, & William J. Valentine. (2019). Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. Journal of Medical Economics. 23(1). 98–105. 37 indexed citations

11.

Pollock, Richard F., Barrie Chubb, William J. Valentine, & Simon Heller. (2018). Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. Diabetes Metabolic Syndrome and Obesity. Volume 11. 217–226. 7 indexed citations

12.

Hunt, Barnaby, et al.. (2017). Evaluation of the long‐term cost‐effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes Obesity and Metabolism. 19(6). 842–849. 19 indexed citations

13.

Mezquita‐Raya, Pedro, et al.. (2017). Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Therapy. 8(2). 401–415. 14 indexed citations

14.

Hunt, Barnaby, Michelle Mocarski, William J. Valentine, & J Langer. (2017). IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes Therapy. 8(3). 531–544. 16 indexed citations

15.

Hunt, Barnaby, Michelle Mocarski, William J. Valentine, & J Langer. (2017). Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. Advances in Therapy. 34(4). 954–965. 15 indexed citations

16.

Pollock, Richard F., J. Chilcott, Gorden Muduma, & William J. Valentine. (2012). Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK. Journal of Medical Economics. 16(2). 249–259. 2 indexed citations

17.

Langer, J, Barnaby Hunt, & William J. Valentine. (2012). PDB56 Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients With Type 2 Diabetes Failing Metformin Monotherapy. Value in Health. 15(4). A180–A181. 1 indexed citations

18.

Varol, N., et al.. (2012). PDB37 Cost-Effectiveness of Adding Twice-Daily Exenatide to Basal Insulin in Patients With Type 2 Diabetes in Scotland. Value in Health. 15(7). A500–A500. 1 indexed citations

19.

Valentine, William J., Johan Jendle, Markku Saraheimo, et al.. (2011). Evaluating the cost‐effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabetic Medicine. 29(3). 303–312. 16 indexed citations

20.

Smith‐Palmer, Jayne, et al.. (2009). Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea. Value in Health. 12. S55–S61. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact